Nanjing Leads Biolabs Co.,ltd

This study is testing an experimental drug called LBL-034 in people whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors. About 342 adults will take part in this early…

This study tests a new drug (LBL-024) combined with a standard chemotherapy (paclitaxel) in about 110 adults with ovarian cancer that has stopped responding to platinum-based treatments. The goal is to see if the combination can shrink tumors and delay cancer growth. Participants…

This study tests whether a new drug called LBL-024, when combined with other medicines, can shrink or control advanced solid tumors. About 140 adults aged 18 to 75 with advanced cancer will receive the treatment. The main goal is to see how many patients' tumors shrink or disappe…

This early-stage study tests a single injection of a new drug, LBL-047, in healthy adults and people with mild-to-moderate systemic lupus erythematosus (SLE). The main goal is to check safety and side effects, and to see how the drug moves through the body. About 112 participants…

This study tests a new drug called LBL-024, alone or with chemotherapy, in people whose triple negative breast cancer has come back or spread. The goal is to see if it can shrink tumors and control the disease. About 220 adults with this aggressive cancer type will take part.

This study tests a new drug called LBL-024 combined with other medicines in 230 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. Participants will receive the drug …

This study tests a new drug called LBL-024 combined with standard chemotherapy (etoposide and platinum) as a first treatment for people with advanced neuroendocrine carcinoma (NEC), a rare and aggressive cancer. About 178 adults aged 18-75 will take part to see if the combo shrin…

This study tests a new drug called LBL-024 combined with other medicines in about 110 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the combination can shrink tumors or stop them from growing. Participants will receiv…

This study tests a new drug called LBL-024 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 396 adults aged 18-80 will take part.

This study tests a new drug called LBL-024 combined with other medicines in 110 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the combination can shrink tumors or stop them from growing. Participants will receive the …

This study is testing a new drug called LBL-024, either alone or combined with other treatments (LBL-007 or toripalimab), in people with advanced melanoma that has spread. The goal is to see if these combinations can shrink tumors or slow the disease. About 200 adults will take p…